Morbidity and mortality in common variable immune deficiency over 4 decades

Area of Science:

• Immunology
• Clinical Medicine
• Epidemiology

Background:

• Common variable immune deficiency (CVID) is a primary immunodeficiency characterized by low immunoglobulin levels and impaired antibody production.
• Long-term outcomes and risk factors for mortality in CVID patients are not fully understood, necessitating comprehensive analysis.

Purpose of the Study:

• To analyze the demographics, immunologic parameters, medical complications, and mortality statistics of a large cohort of CVID patients over four decades.
• To identify factors associated with reduced survival and increased mortality risk in individuals with CVID.

Main Methods:

• Retrospective analysis of demographic, clinical, and laboratory data from 473 CVID patients followed for over 40 years.
• Statistical analysis to compare patient survival with age- and sex-matched population controls and to identify risk factors for mortality.

Main Results:

• The study identified key immunoglobulin levels (median IgG: 246 mg/dL, IgA: 8 mg/dL, IgM: 21 mg/dL) and noted 22.6% had IgG < 100 mg/dL.
• Males were diagnosed earlier than females. 94% experienced infections, and 68% had noninfectious complications including autoimmunity, chronic lung disease, and gastrointestinal issues.
• Mortality was 19.6%, significantly lower than controls. Noninfectious complications (HR=10.95) and specific conditions like lymphoma, hepatitis, and lung/GI disease were strongly associated with increased mortality.

Conclusions:

• CVID patients have significantly reduced survival rates compared to the general population.
• Noninfectious complications, particularly lymphoma, hepatitis, and lung/gastrointestinal diseases, are major drivers of mortality in CVID.
• Managing infections and noninfectious comorbidities is critical for improving long-term outcomes in CVID patients.